Medicenna Therapeutics presents preclinical MDNA223 BiSKIT data

Medicenna Therapeutics announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT, were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 – 4, 2023, in Toronto, Canada. The poster presentation includes preclinical data demonstrating that the MDNA223 BiSKIT: Showed enhanced IL-2R selectivity and no binding to IL-2R, leading to preferential stimulation of CD8+ T cells over Tregs in human PBMCs, Retained high affinity to PD-1, generating potent blockade of PD-1/PD-L1 mediated exhaustion of T cells, Induced durable proliferation and expansion of CD8+ T cells in the periphery, and enhanced tumor infiltration of functionally active CD8+ T cells, Demonstrated superior efficacy and survival benefit in multiple syngeneic tumor models, including “cold” tumors compared to co-administration of anti-PD1 and IL-2 agonist, Synergized with agonist of the STING pathway to enhance tumor inhibition and promote an abscopal effect as demonstrated by shrinkage of the untreated tumor on opposite flank, Synergized with STING agonist and enhanced tumor inhibition by abscopal effect, Enhanced tumor response while being well-tolerated in a step-up dosing setting.